1. France Stocks

  2. •

    Healthcare

  3. •

    Medical - Devices
Theraclion S.A.

Theraclion S.A.

TCLIF
Theraclion S.A.US flagOther OTC
0.53
USD
- -
- -
25.09MMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
Revenue per Share
- -
0.21
0.35
0.28
0.32
0.22
0.18
0.05
0.06
0.04
0.04
0.02
- -
Basic EPS, GAAP
-1.35
-1.24
-1.48
-1
-0.82
-0.71
-0.24
-0.24
-0.16
-0.17
-0.08
-0.12
- -
Free Cash Flow per Basic Share
-1.47
-1.51
-1.35
-1.27
-0.91
-0.57
-0.25
-0.21
-0.17
-0.19
-0.06
-0.06
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
-4.96
-5.26
-6.01
-0.95
-0.77
-0.67
-0.19
-0.19
-0.11
-0.12
-0.03
-0.07
- -
Tangible Book Value per Share
-1.56
0.51
-0.13
0.67
0.31
-0.18
-0.07
-0.25
-0.1
-0.03
0.09
-0.02
- -
Basic Weighted Avg Shares
3
4
4
7
8
9
16
16
23
30
47
47
60
Sales/Revenue/Turnover
- -
1
2
2
2
2
3
1
1
1
2
1
- -
Operating Margin (%)
-31,355.88
-620.13
-472.98
-402.43
-291.99
-361.75
-168.66
-569.27
-356.55
-507.74
-172.23
-819.62
- -
Depreciation Expense
- -
- -
- -
- -
- -
1
- -
- -
- -
- -
3
1
- -
Net Income, GAAP
-4
-5
-6
-7
-6
-6
-4
-4
-4
-5
-4
-6
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
-28,350.41
-579.48
-418.88
-351.31
-256.04
-318.56
-136.24
-524.9
-253.92
-401.83
-201.68
-693.45
- -
Working Capital
1
5
4
9
7
2
3
4
4
5
12
5
- -
LT Debt
6
4
- -
- -
- -
- -
- -
4
3
3
2
1
- -
Total Equity
-4
3
1
6
3
-1
- -
-3
-1
1
6
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
- -
Free Cash Flow
- -
- -
- -
Net Income, GAAP
- -
- -
- -
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
2
2024
- -
- -
- -
- -
1
2025
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
-0.08
2024
- -
- -
- -
- -
-0.12
2025
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -

Company Description

APIChat
CEO
Martin Deterre
Full Time Employees
28
Sector
Healthcare
Industry
Medical - Devices
Address
102 Rue Etienne Dolet Malakoff France 92240
IPO Date
Apr 22, 2019
Website
theraclion.com
Similar Companies
United American Healthcare Corporation (UAHC)
Viveve Medical, Inc. (VIVE)
elexxion AG (E8X.DE)
Fuse Medical, Inc. (FZMD)
Coloplast A/S (CLPBF)
Neovasc Inc. (NVCN)
Business
Theraclion SA develops, manufactures, and markets high-intensity focused ultrasound (HIFU) echotherapy equipment for non-invasive treatment of vascular and oncological conditions; its core products include SONOVEIN, a robotic platform for varicose vein ablation featuring the upgraded SONOVEIN HD version with advanced imaging from SuperSonic Imagine, ECHOPULSE for outpatient treatment of thyroid nodules and breast fibroadenoma, and EPack, a single-use disposable for skin protection and image optimization. The company operates primarily in Europe with commercial expansion into the Middle East, pursues regulatory progress in the United States and China, and targets vascular specialists, phlebologists, endocrinologists, and radiologists in outpatient settings. Founded in 2004 and headquartered in Malakoff, France, Theraclion recently refocused strategically on the varicose vein market by ceasing commercialization of ECHOPULSE for thyroid treatment and not renewing its CE marking under new European MDR regulations; it secured €6.58 million in convertible bond financing led by shareholders Furui and Unigestion with €3 million drawn in early 2025, formed a joint venture with Furui to accelerate Chinese market entry including product registration and local manufacturing, advanced U.S. FDA submission for SONOVEIN planned for late 2025 with 12-month clinical follow-up results expected by summer 2025, and launched the third-generation SONOVEIN HD platform integrating procedural data analytics.